Navigation Links
Abbott's XIENCE V(R) Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long-Term Safety Results in SPIRIT III Trial
Date:9/21/2009

SAN FRANCISCO, Sept. 21 /PRNewswire-FirstCall/ -- Long-term data presented today from the SPIRIT III pivotal U.S. clinical trial demonstrated that the observed clinical advantages of Abbott's market-leading XIENCE V(R) Everolimus Eluting Coronary Stent System continued to increase as compared to the TAXUS(R) Express2 Paclitaxel-Eluting Coronary Stent System (TAXUS). At three years, XIENCE V demonstrated a 43 percent reduction in the risk of major adverse cardiac events (MACE) compared to TAXUS (9.1 percent for XIENCE V vs. 15.7 percent for TAXUS, p-value=0.003)*. MACE is an important composite clinical measure of safety and efficacy outcomes for patients, defined as cardiac death, heart attack (myocardial infarction or MI), or ischemia-driven target lesion revascularization (ID-TLR driven by lack of blood supply). The three-year results from the SPIRIT III trial will be presented today by Gregg W. Stone, M.D., professor of medicine at Columbia University Medical Center, during the 2009 Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco.

"The SPIRIT III results clearly demonstrate that at three years, patients continue to benefit from having been treated with the XIENCE V stent rather than the TAXUS stent, with fewer repeat cardiac procedures and fewer heart attacks in patients who received XIENCE V," said Dr. Stone, who is also immediate past chairman of the Cardiovascular Research Foundation, New York; and principal investigator of the SPIRIT III trial.

XIENCE V demonstrated an impressive low rate of very late stent thrombosis (one to three years) with no additional events between two and three years. Per protocol, XIENCE V demonstrated a 0.2 percent** very late stent thrombosis rate compared to 1.0 percent for TAXUS (p-value=0.10) at three years. Per Academic Research Consortium (ARC) definition of definite/probable stent thrombosis, the rate of very
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Abbotts Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years
2. Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
3. Abbotts XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
4. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
5. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
6. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
7. SPIRIT II Explores Long-Term Performance of XIENCE V Stent
8. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
9. 18 month Follow-up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory, Aggressive Non-Hodgkins Lymphoma Continues to Demonstrate Significant Improvement in Complete Remission and Progression Free Survival Over Standard Chemotherap
10. Clinical Genomics Continues Progress in Developing Biomarker Portfolio for Colorectal Cancer Testing
11. Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 30, 2014  Electronic health records uptake in ... of government initiatives and the considerable resources – ... invested over the past five years. Electronic health ... and U.S. clinicians use them on a daily ... Frost & Sullivan,s newest ...
(Date:10/30/2014)... 2014  Nektar Therapeutics (Nasdaq: NKTR ) ... ended September 30, 2014 on Thursday, November 6, 2014, ... Robin , president and chief executive officer, will host ... 5:00 p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT). ... audio-only Webcast of the conference call can be accessed ...
(Date:10/30/2014)... 2014  CytRx Corporation (NASDAQ: CYTR ... in oncology, today announced an upcoming presentation highlighting ... aldoxorubicin.  The presentation, titled, "Drug Conjugates Bind Covalently ... by Sant P. Chawla , M.D., F.R.A.C.P., ... investigator of the Company,s ongoing global, pivotal Phase ...
Breaking Medicine Technology:Electronic Health Record Usability: CIOs Weigh In 2Electronic Health Record Usability: CIOs Weigh In 3Electronic Health Record Usability: CIOs Weigh In 4Nektar to Announce Financial Results for the Third Quarter 2014 on Thursday, November 6, 2014, After Close of U.S.-Based Financial Markets 2CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 2CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 3CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 4
(Date:10/30/2014)... group at the DFG Research Center for Regenerative Therapies ... (CRTD) demonstrated for the first time the in vitro ... dimensions from mouse embryonic stem cells. Correct spatial organization ... dorsal/ventral axis was observed., This study has been published ... Reports " on 30.10.2014 ., For many years Elly ...
(Date:10/30/2014)... October 30, 2014 Nutrition Leaders, a ... weight loss aids, and more, is currently hosting a ... is already underway, is open to U.S. residents age ... December 15, 2014. One lucky winner will then be ... a $100 gift card to NutritionLeaders.com. , Nutrition Leaders’ ...
(Date:10/30/2014)... 2014 Graphics, coding, typography and search ... the craft of web design and require thorough knowledge ... simpler solution to create a website can be as ... information, customer reviews and Facebook posts all accumulate on ... the next evolution of how a business can develop ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 High ... exclusive concepts in the medical-grade skin care domain: ... development of uniquely potent topical dermatological products, today ... ( http://www.RefinitySkinScience.com ) with patented COSMEDERM®-7 anti-irritant technology. ... acid concentrations (50% and 70%) and a low ...
(Date:10/30/2014)... PreDiabetes Centers , the pioneer ... shoppers with a supply of sugardown®, a chewable dietary ... blood sugar spikes. Learning how to control blood sugar ... of a diabetes prevention plan. , Shoppers who spend ... tube of sugardown. The offer expires November 30. ...
Breaking Medicine News(10 mins):Health News:Reconstruction of a patterned piece of spinal cord in 3-D culture 2Health News:Nutrition Leaders Announces Gift Card Sweepstakes 2Health News:Facebook Websites In Thirty-Seconds 2Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 2Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 3Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 4Health News:PreDiabetes Treatment Company Offers PreD Store Shoppers Supplements to Support Healthy Blood Sugar 2
... , This release is available in German ... in Health Care (IQWiG) has investigated the reliability of diagnosing ... and the benefit that the test results can have for ... According to the report, the available studies do not reveal ...
... detect brain damage in amateur boxers. Deterioration of nerve cells ... This is shown in a new study from the Sahlgrenska ... results of the study conducted by researchers at the Sahlgrenska ... published in the current issue of the scientific journal ...
... shown that patients who receive night home hemodialysis live ... from deceased donors. In a study entitled, ... transplant recipients," published in the international September issue of ... patients were followed for up to 12 years. Night ...
... , , , NEW ORLEANS, Aug. 20 ... the Rouses Market, 4500 Tchoupitoulas Street , Ochsner ... R o uses Markets, the largest independent grocer in Louisiana, will announce ... www.cho o se-healthy.org ." ...
... them individually, study finds , THURSDAY, Aug. 20 (HealthDay ... one nostril detects scents slightly differently than the other, ... in perception result from small differences in the time ... or the other. They call the difference a "binaural" ...
... disorientation occurs quickly without the sun, moon for guidance, , ... losing their way in the wilderness, unwittingly walking in circles ... are true. Without the sun, a compass or a landmark, ... or a desert ended up back where they started, according ...
Cached Medicine News:Health News:Reliability and benefit of diagnostic procedure for asthma in young children is unclear 2Health News:Reliability and benefit of diagnostic procedure for asthma in young children is unclear 3Health News:Reliability and benefit of diagnostic procedure for asthma in young children is unclear 4Health News:Blood test can detect brain damage in amateur boxers 2Health News:Night home hemodialysis shown to be as good as transplant in treating kidney failure 2Health News:Ochsner and Rouses Markets Partner for Choose Healthy Initiative 2Health News:Ochsner and Rouses Markets Partner for Choose Healthy Initiative 3Health News:Nostrils Compete to Relay Key Fragrance 2Health News:Lost Hikers, Backpackers Really Do Walk in Circles 2Health News:Lost Hikers, Backpackers Really Do Walk in Circles 3
Dual offset femoral stems, hip stems that provide unique and competitive features....
Cementless hip stem revisions offering optimal version setting for each patient. Compatible with modular link ceramic or cobalt chromium femoral heads with up to 4 neck lengths, or the link saddle de...
The proximally modular S-ROM Total Hip System provides custom capability at non-custom prices and is competitive with conventional porous coated systems....
Exactech's AcuMatch C-Series (Cemented Femoral Stem) is designed to provide solutions to the problems which compromise both the short and long term successful outcome of cemented hip arthroplasty....
Medicine Products: